We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Orkambi was initially approved in Europe in 2015 for patients with CF ages 12 years and older who have two copies of the F508del mutation and was later expanded to include children ages six to 11 years.